Biotech consultancy supporting

biopharmaceutical development globally

GRA: The Biotech Consultancy

GreyRigge Associates or GRA is a biotech consultancy working internationally helping both small and large biopharmaceutical companies to develop medicines. GRA offer both technical and commercial support for biotech products including vaccines, cell therapies, monoclonal antibodies & gene therapies.

GRA offer both consultancy and training services to clients covering CMC, process and analytical development, formulation of biologics and pre-clinical and clinical assay development.  GRA also have experience in product characterisation and supporting the CMC elements of regulatory submissions and interactions.  GRA can apply QbD practices to processes, including advising on appropriate use of DoE.   Please contact GRA on how we might help.

Meet Lee, the Principal consultant of GRA

Lee founded GRA and has a passion for biotech & data driven results.  GRA’s aim is to help companies, or more specifically, their people drive programs forward, achieve objectives and grow the business.

Find out more about

GRA & Lee.

3x3 placeholder

A history of success

Process development – including process design, optimisation through to validation

“Working with GRA has many advantages. One example is the extraordinary network of Associates from different scientific areas that GRA has built over the years. This brings specific know-how to exactly where it is needed for only as long it is needed; a very sophisticated approach. A combination of Lee’s personal expertise combined with the know-how from the Associates brings project development to the next level”

Dr. Matthias Mullner
SVP Technical Operations

Merck Sharp & Dohme GmbH

Read our testimonials on what clients say about GRA

Formulation Strategies For COVID 19 Vaccines

posted by: Lee Smith posted on: August 17, 2021 categories: Development, Manufacturing, Talks

Conducting well-designed structured studies is important when formulating any vaccine. For live viral vaccines, some challenges include limited analytical tools and inherent variability that make evaluation difficult.